134 related articles for article (PubMed ID: 9751755)
1. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac.
Skorski T; Wlodarski P; Daheron L; Salomoni P; Nieborowska-Skorska M; Majewski M; Wasik M; Calabretta B
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11858-62. PubMed ID: 9751755
[TBL] [Abstract][Full Text] [Related]
2. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
Skorski T; Bellacosa A; Nieborowska-Skorska M; Majewski M; Martinez R; Choi JK; Trotta R; Wlodarski P; Perrotti D; Chan TO; Wasik MA; Tsichlis PN; Calabretta B
EMBO J; 1997 Oct; 16(20):6151-61. PubMed ID: 9321394
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation.
Cirinnà M; Trotta R; Salomoni P; Kossev P; Wasik M; Perrotti D; Calabretta B
Blood; 2000 Dec; 96(12):3915-21. PubMed ID: 11090078
[TBL] [Abstract][Full Text] [Related]
4. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Wasik M; Trotta R; Kanakaraj P; Salomoni P; Antonyak M; Martinez R; Majewski M; Wong A; Perussia B; Calabretta B
Blood; 1998 Jan; 91(2):406-18. PubMed ID: 9427693
[TBL] [Abstract][Full Text] [Related]
5. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant.
Salomoni P; Wasik MA; Riedel RF; Reiss K; Choi JK; Skorski T; Calabretta B
J Exp Med; 1998 Jun; 187(12):1995-2007. PubMed ID: 9625759
[TBL] [Abstract][Full Text] [Related]
6. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.
Perrotti D; Bonatti S; Trotta R; Martinez R; Skorski T; Salomoni P; Grassilli E; Lozzo RV; Cooper DR; Calabretta B
EMBO J; 1998 Aug; 17(15):4442-55. PubMed ID: 9687511
[TBL] [Abstract][Full Text] [Related]
7. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
Nieborowska-Skorska M; Slupianek A; Skorski T
Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
Gerboth S; Frittoli E; Palamidessi A; Baltanas FC; Salek M; Rappsilber J; Giuliani C; Troglio F; Rolland Y; Pruneri G; Kreutmair S; Pallavicini I; Zobel M; Cinquanta M; Minucci S; Gomez C; Santos E; Illert AL; Scita G
Leukemia; 2018 Mar; 32(3):820-827. PubMed ID: 28819285
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
Jain SK; Langdon WY; Varticovski L
Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
[TBL] [Abstract][Full Text] [Related]
11. BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells.
Mizuchi D; Kurosu T; Kida A; Jin ZH; Jin A; Arai A; Miura O
Biochem Biophys Res Commun; 2005 Jan; 326(3):645-51. PubMed ID: 15596148
[TBL] [Abstract][Full Text] [Related]
12. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
Hoover RR; Gerlach MJ; Koh EY; Daley GQ
Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
[TBL] [Abstract][Full Text] [Related]
13. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
Lin H; Monaco G; Sun T; Ling X; Stephens C; Xie S; Belmont J; Arlinghaus R
Oncogene; 2005 May; 24(20):3246-56. PubMed ID: 15735695
[TBL] [Abstract][Full Text] [Related]
14. Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells.
Nieborowska-Skorska M; Hoser G; Rink L; Malecki M; Kossev P; Wasik MA; Skorski T
Cancer Res; 2006 Apr; 66(8):4108-16. PubMed ID: 16618731
[TBL] [Abstract][Full Text] [Related]
15. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
[TBL] [Abstract][Full Text] [Related]
16. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.
Ren SY; Bolton E; Mohi MG; Morrione A; Neel BG; Skorski T
Mol Cell Biol; 2005 Sep; 25(18):8001-8. PubMed ID: 16135792
[TBL] [Abstract][Full Text] [Related]
17. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7.
Issaad C; Ahmed M; Novault S; Bonnet ML; Bennardo T; Varet B; Vainchenker W; Turhan AG
Leukemia; 2000 Apr; 14(4):662-70. PubMed ID: 10764152
[TBL] [Abstract][Full Text] [Related]
18. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells.
Le Y; Xu L; Lu J; Fang J; Nardi V; Chai L; Silberstein LE
Am J Hematol; 2009 May; 84(5):273-8. PubMed ID: 19358301
[TBL] [Abstract][Full Text] [Related]
19. KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts.
Andersson BS; Collins VP; Kurzrock R; Larkin DW; Childs C; Ost A; Cork A; Trujillo JM; Freireich EJ; Siciliano MJ
Leukemia; 1995 Dec; 9(12):2100-8. PubMed ID: 8609723
[TBL] [Abstract][Full Text] [Related]
20. Prostate apoptosis response gene-4 (par-4) abrogates the survival function of p185(BCR-ABL) in hematopoietic cells.
Kukoc-Zivojnov N; Puccetti E; Chow KU; Bergmann M; Ruthardt M; Hoelzer D; Mitrou PS; Weidmann E; Boehrer S
Exp Hematol; 2004 Jul; 32(7):649-56. PubMed ID: 15246161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
